Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...
Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...
Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...
In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...
A novel nickel-free, low-profile TAVI valve shows promise in treating severe aortic stenosis, according to first-in-human (FIH) and early feasibility study (EFS) data. The balloon-expandable Siegel ...
Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...
Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...
Irvine-based Edwards Lifesciences Corp. today announced newly presented data from several of its clinical trials. The data, presented at the annual New York Valves 2026 conference, included seven-year ...
The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results